Öztürk, Hakan

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/6948
Name Variants
Ozturk, Hakan
Oezturk, Hakan
Job Title
Email Address
hakan.ozturk@ieu.edu.tr
Main Affiliation
09.04. Surgical Sciences
Status
Current Staff
Website
ORCID ID
0000-0002-4962-7707
Scopus Author ID
55920108000
Turkish CoHE Profile ID
DF212F6426B26A43
Google Scholar ID
C4YHnsoAAAAJ
WoS Researcher ID
V-6536-2017

Sustainable Development Goals

11

SUSTAINABLE CITIES AND COMMUNITIES
SUSTAINABLE CITIES AND COMMUNITIES Logo

0

Research Products

4

QUALITY EDUCATION
QUALITY EDUCATION Logo

0

Research Products

8

DECENT WORK AND ECONOMIC GROWTH
DECENT WORK AND ECONOMIC GROWTH Logo

0

Research Products

12

RESPONSIBLE CONSUMPTION AND PRODUCTION
RESPONSIBLE CONSUMPTION AND PRODUCTION Logo

0

Research Products

9

INDUSTRY, INNOVATION AND INFRASTRUCTURE
INDUSTRY, INNOVATION AND INFRASTRUCTURE Logo

0

Research Products

15

LIFE ON LAND
LIFE ON LAND Logo

0

Research Products

6

CLEAN WATER AND SANITATION
CLEAN WATER AND SANITATION Logo

0

Research Products

1

NO POVERTY
NO POVERTY Logo

0

Research Products

7

AFFORDABLE AND CLEAN ENERGY
AFFORDABLE AND CLEAN ENERGY Logo

0

Research Products

10

REDUCED INEQUALITIES
REDUCED INEQUALITIES Logo

0

Research Products

14

LIFE BELOW WATER
LIFE BELOW WATER Logo

0

Research Products

2

ZERO HUNGER
ZERO HUNGER Logo

0

Research Products

13

CLIMATE ACTION
CLIMATE ACTION Logo

0

Research Products

5

GENDER EQUALITY
GENDER EQUALITY Logo

0

Research Products

16

PEACE, JUSTICE AND STRONG INSTITUTIONS
PEACE, JUSTICE AND STRONG INSTITUTIONS Logo

0

Research Products

17

PARTNERSHIPS FOR THE GOALS
PARTNERSHIPS FOR THE GOALS Logo

0

Research Products

3

GOOD HEALTH AND WELL-BEING
GOOD HEALTH AND WELL-BEING Logo

1

Research Products
Documents

49

Citations

376

h-index

11

Go to Scopus profile
Documents

44

Citations

284

Go to WoS profile
Scholarly Output

5

Articles

4

Views / Downloads

5/16

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

5

Scopus Citation Count

6

WoS h-index

1

Scopus h-index

2

Patents

0

Projects

0

WoS Citations per Publication

1.00

Scopus Citations per Publication

1.20

Open Access Source

4

Supervised Theses

0

Google Analytics Visitor Traffic

JournalCount
Lasers in Medical Science1
Reports of Practical Oncology and Radiotherapy1
Urology Annals1
Urology Case Reports1
World Journal of Clinical Cases1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2022 - 20245
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    Editorial
    Covid-19 Outbreak May Increase Mortality Rates in Genitourinary Cancers Comment
    (Wolters Kluwer Medknow Publications, 2022) Ozturk, Hakan; Gumus, Can
    [Abstract Not Available]
  • Thumbnail Image
    Article
    Citation - WoS: 1
    Citation - Scopus: 1
    A Novel Technique for Thulium Laser Enucleation of the Prostate: Anterior Releasing With Thulep (arth Technique)
    (Springer london ltd, 2024) Öztürk, Hakan
    Thulium laser enucleation of the prostate (ThuLEP) is a highly effective approach to the treatment of benign prostatic hyperplasia. We present here a description of the ARTh Technique and the benefits it offers in terms of improved visualization, short operation times, and easy recognition of the dissection plane, describing specifically the anterior release (AR) technique using ThuLEP(Th). Included in this retrospective study were 32 consecutive patients operated on between January 2022-November 2022. Parameters were measured before and after the procedure: the International Prostate Symptom Score(IPSS), maximum flow rate(Qmax), post-void residual urine(PVR) prostate-specific antigen(PSA), prostate volume, operation-time, morcellation-time, catheterization-time and presence of transient urinary incontinence, and compared. The median age of patients undergoing enucleation of the prostate using the ARTh technique was 64 years (range: 44-83). The median prostate volume of the patients was 83.5 ml(50-128 ml), preoperative-IPSS was 24.8(15-33), postoperative-IPSS was 7(5-11), preoperative-Qmax was 8.1 ml/Sects. (5-11.5 ml/sec), postoperative-Qmax was 26.9 ml/Sect. (20.8-34 ml/sec), preoperative-PVR was 145 ml(75-258 ml), postoperative-PVR was 36.2 ml(0-66 ml), total operation time was 51.4 min(28-82 min), enucleation time was 36.9 min(19-51 min) and morcellation time was 15.3 min(8-27 min). The ARTh technique is a safe procedure that allows the surgeon to easily recognize and adhere to the defined dissection plane, thus decreasing operation times, significantly reducing the rate of postoperative transient urinary incontinence (TUI).
  • Thumbnail Image
    Article
    Citation - WoS: 1
    Citation - Scopus: 2
    Cutaneous Metastasis of Bladder Urothelial Carcinoma; a Rare Conditions
    (Elsevier Science Inc, 2022) Oztuerk, Hakan; Yurtsever, Selin; Ozer, Arzum; Arslan, Cagatay; Tekeli, Aysun; Pehlivan, Fatma Seher
    Cutaneous is an extremely rare metastatic area of bladder urothelial carcinoma. Pure cutaneous metastasis without systemic metastasis is very rare and less than ten cases have been reported in the literature. Our patient had various lymphatic fistulas to her skin due to pelvic lymphadenectomy and radiotherapy in her previous cervical cancer. We believe that the most probable mechanism underlying our patient's cutaneous metastasis is a lymphatic spread via those lymphatic fistulas. Immunotherapy is a very important option for patients who cannot receive cisplatin. This is the second case in the literature to apply immunotherapy in the setting of cutaneous metastasis of bladder cancer.
  • Thumbnail Image
    Article
    Evaluation of Response To Gemcitabine Plus Cisplatin-Based Chemotherapy Using Positron Emission Computed Tomography for Metastatic Bladder Cancer
    (Baishideng Publishing Group Inc, 2023) Öztürk, Hakan; Karapolat, İnanç
    BACKGROUNDThe purpose of the present study was to examine retrospectively the contribution of (18)Fluorodeoxyglucose positron emission tomography computed tomography ((18)FDG-PET/CT) to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer. AIMTo evaluate the response to Gemcitabine plus Cisplatin -based chemotherapy using (18)FDG-PET/CT imaging in patients with metastatic bladder cancer. METHODSBetween July 2007 and April 2019, 79 patients underwent (18)FDG-PET/CT imaging with the diagnosis of Metastatic Bladder Carcinoma (M-BCa). A total of 42 patients (38 male, 4 female) were included in the study, and all had been administered Gemcitabine plus Cisplatin-based chemotherapy. After completion of the therapy, the patients underwent a repeat (18)FDG-PET/CT scan and the results were compared with the PET/CT findings before chemotherapy according to European Organisation for the Research and treatment of cancer criteria. Mean age was 66.1 years and standard deviation was 10.7 years (range: 41-84 years). RESULTSOf the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent. CONCLUSION(18)FDG-PET/CT can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from PET/CT scans may be useful in the planning of secondline and thirdline chemotherapy.
  • Thumbnail Image
    Article
    Citation - WoS: 3
    Citation - Scopus: 3
    Role of 18f-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Restaging of Adrenocortical Carcinoma
    (Vıa Medıca, 2023) Öztürk, Hakan
    Background: The objective was to retrospectively evaluate the contribution of fluorodeoxyglucose [F-18] positron emission tomography/computed tomography ((18)FDG-PET/CT) to the re-staging of adrenocortical carcinoma (ACC). Materials and methods: A total of 16 patients (10 males and 6 females), who underwent adrenalectomy due to adrenocortical carcinoma and (18)FDG-PET/CT scan to re-stage the tumor between July 2007 and April 2013, were included in the present study. The mean age was 53.37 +/- 13.91 years (min: 30, max: 74) The patients were required to fast for six hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 h after the intravenous injection of 555 MBq of F-18 FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. Results: Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of (18)FDG-PET/CT were 100%, 83.3%, 90.9%, 83.3%, and 93.7%, respectively. Conclusion: 18FDG-PET/CT detects local recurrence and/or distant metastases with high accuracy in the re-staging of operated adrenocortical carcinoma. It is considered that the procedure could play an important role in treatment decision after the operation and post- operative follow-up and could influence the entire decision-making process.